Updated Dosing Guidelines Issued for Semaglutide and Tirzepatide in 2026

New dosing guidelines for Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound) have been released for 2026, based on recent clinical trials and real-world data. These updates refine starting doses, escalation intervals, and maximum recommended amounts, with separate recommendations for diabetes and weight loss. The changes aim to improve tolerability and patient outcomes while preserving efficacy, emphasizing patient education and adherence to prescribed protocols.